Is intravenous iron infusion appropriate for treating restless legs syndrome?

Iron Infusion for Restless Legs Syndrome

Intravenous iron infusion is appropriate and strongly recommended for treating restless legs syndrome in adults with appropriate iron parameters, specifically IV ferric carboxymaltose as first-line therapy. 1

Treatment Algorithm Based on Iron Status

The 2025 American Academy of Sleep Medicine guidelines establish a clear hierarchy for iron therapy in RLS:

For Adults with RLS (General Population)

Strong Recommendations:

• IV ferric carboxymaltose is the only IV iron formulation with a strong recommendation (moderate certainty of evidence) 1
• Check iron parameters before treatment: serum ferritin and transferrin saturation (TSAT)
• Target ferritin levels between 75-100 ng/mL as the threshold for supplementation 1

Conditional Recommendations for IV Iron:

• IV low molecular weight iron dextran (very low certainty of evidence) 1
• IV ferumoxytol (very low certainty of evidence) 1

Oral Iron Alternative:

• Ferrous sulfate is suggested with moderate certainty of evidence, but is less effective than IV formulations 1

For Adults with RLS and End-Stage Renal Disease

IV iron sucrose is specifically recommended when ferritin < 200 ng/mL AND transferrin saturation < 20% (conditional recommendation, moderate certainty of evidence) 1

This represents a different threshold than the general RLS population, reflecting the altered iron metabolism in dialysis patients.

Clinical Reasoning

The guideline prioritization of IV ferric carboxymaltose reflects:

1. Efficacy data: Meta-analysis shows IV iron reduces International RLS Study Group rating scale (IRLS) scores by -3.78 points compared to placebo 2, with IV ferric carboxymaltose specifically showing improvement of -2.79 points 3

2. Superiority over oral iron: While oral iron works, IV formulations bypass gastrointestinal absorption limitations that reduce oral iron efficacy 4

3. Safety profile: Adverse events are generally mild (transient hypophosphatemia being most common) and not significantly different from placebo overall (RR 1.48,95% CI 0.97-2.25) 2

4. Disease-modifying potential: Iron addresses the core pathophysiology of brain iron deficiency in RLS, not just symptoms 4, 5

Key Iron Parameters for Patient Selection

Critical caveat: Transferrin saturation ≤ 35% is a more sensitive predictor of treatment response than ferritin alone 4. Use both markers together:

• Ferritin threshold: < 75 ng/mL warrants supplementation; target > 100 ng/mL 1, 6
• TSAT threshold: Consider treatment when ≤ 35% even with higher ferritin 4
• Assay variation warning: Ferritin measurements vary significantly by manufacturer (Beckman vs. Roche can differ by 50-60% at the same true level), so know your laboratory's assay and adjust thresholds accordingly 7

Positioning in Overall Treatment Strategy

Iron therapy (particularly IV) now ranks alongside α2δ ligands (gabapentin, pregabalin, gabapentin enacarbil) as first-line treatment, ahead of dopamine agonists which are now discouraged due to long-term augmentation risk 1, 5, 6.

The treatment hierarchy is:

1. First-line: α2δ ligands (gabapentin enacarbil, gabapentin, pregabalin) - all strong recommendations 1
2. First-line: IV ferric carboxymaltose when iron parameters are appropriate - strong recommendation 1
3. Second-line: Oral iron, opioids, other interventions - conditional recommendations 1
4. Discouraged: Dopamine agonists (pramipexole, ropinirole, rotigotine) due to augmentation risk with long-term use 1

Practical Implementation

Before prescribing any RLS treatment, address exacerbating factors: alcohol, caffeine, antihistamines, serotonergic medications, antidopaminergic medications, and untreated obstructive sleep apnea 1

For iron-deficient RLS patients:

• Order ferritin AND transferrin saturation
• If ferritin < 75 ng/mL or TSAT ≤ 35%: proceed with IV ferric carboxymaltose (total dose ≥ 1000 mg based on research evidence) 4
• Reassess at 2-12 weeks for symptom improvement on IRLS scale 2
• Monitor for mild adverse effects (hypophosphatemia) but serious events are rare 4

Special populations:

• Dialysis patients: Use IV iron sucrose with different thresholds (ferritin < 200 ng/mL AND TSAT < 20%) 1
• Children: Use oral ferrous sulfate when ferritin < 50 ng/mL 1
• Pregnancy: Iron therapy is appropriate but consider pregnancy-specific safety profiles 1

The evidence strongly supports IV iron as disease-modifying therapy that addresses RLS pathophysiology rather than merely masking symptoms, making it appropriate first-line treatment when iron parameters indicate deficiency.